Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide · PHENOBARBITAL 16.2 mg/1; HYOSCYAMINE SULFATE .1037 mg/1; ATROPINE SULFATE .0194 mg/1; SCOPOLAMINE HYDROBROMIDE .0065 mg/1 · Tablet · Oral · Winder Laboratories, LLC
NDC 75826-0118-10 · 100 TABLET in 1 BOTTLE, PLASTIC · UNAPPROVED DRUG OTHER · View full market →
Just 2 companies supply this market — thin enough that a single exit would be felt immediately. One of its named manufacturing plants, Winder Laboratories, Llc, failed FDA inspectionwithin the last two years — the agency’s most serious outcome. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.
Some pressure is visible, but not much — here’s everything the score found to count.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Advanz Pharma (US) Corp. | PHENOBARBITAL 16.2 mg/1; HYOSCYAMINE SULFATE .1037 mg/1; ATROPINE SULFATE .0194 mg/1; SCOPOLAMINE HYDROBROMIDE .0065 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Winder Laboratories, LLC | PHENOBARBITAL 16.2 mg/1; HYOSCYAMINE SULFATE .1037 mg/1; ATROPINE SULFATE .0194 mg/1; SCOPOLAMINE HYDROBROMIDE .0065 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Advanz Pharma (US) Corp. | PHENOBARBITAL .0194 mg/1; HYOSCYAMINE SULFATE .1037 mg/1; ATROPINE SULFATE 16.2 mg/1; SCOPOLAMINE HYDROBROMIDE .0065 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Winder Laboratories, LLC | PHENOBARBITAL .0194 mg/1; HYOSCYAMINE SULFATE .1037 mg/1; ATROPINE SULFATE 16.2 mg/1; SCOPOLAMINE HYDROBROMIDE .0065 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Advanz Pharma (US) Corp. | ATROPINE SULFATE .0194 mg/1; HYOSCYAMINE SULFATE .1037 mg/1; PHENOBARBITAL 16.2 mg/1; SCOPOLAMINE HYDROBROMIDE .0065 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Winder Laboratories, LLC | ATROPINE SULFATE .0194 mg/1; HYOSCYAMINE SULFATE .1037 mg/1; PHENOBARBITAL 16.2 mg/1; SCOPOLAMINE HYDROBROMIDE .0065 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Phenohytro — NDC 75826-0118-10," retrieved September 3, 2026, https://drugdashboards.com/drug/75826011810.
Free to cite with attribution — see how the data is put together.